BIOYF / RX.V is a rapidly growing marketer of

New Post Public Reply Private Reply Replies (0) Message Board
MikeDDKing

BIOYF / RX.V is a rapidly growing marketer of pharmaceuticals in Canada that I think will be a monster. They also have a nice insecticide business. Here are some reasons I like them:

1. Last quarter they made $0.025/share ignoring one-time items ($0.019 before one-time items). They last traded at $0.55 so they are cheap based upon those earnings. The insecticide business has some seasonality but I'm expecting Q4 to be similar to Q3 due to the growth in the pharmaceutical division.

2. The pharmaceutical business has had massive growth over the past two years. Here is the sales history for the pharmaceutical sales division:

Q3'11 $605K
Q2'11 $465K
Q1'11 $323K
Q4'10 $248K
Q3'10 $192K
Q2'10 $155K
Q1'10 $81K

3. Margins are very high at 78.6% for the last quarter. That means that additional revenue drops rapidly to the bottom line.

4. The pharmaceutical business has been growing rapidly because of the product FeraMAX which is for iron deficiency. It doesn't have the constipation side effect of other drugs which is a big benefit. It is continuing to gain new interest:
http://www.babycenter.ca/thread/26739/low-iron-anyone

5. They have a new topical anesthetic coming out in 2012 which should add to the growth in the pharmaceutical business.
http://finance.yahoo.com/news/BioSyent-Pharma...0&.v=1

6. The CFO has a history of purchasing lots of shares. He recently. His most recent purchase was at $0.485. In addition to the purchase shown in the link below, he also purchased 167,000 shares from 03/15/11-07/22/11 in the $0.107-$0.160 range
http://canadianinsider.com/node/7?menu_tickersearch=rx.v

7. They have a healthy balance sheet with no debt. Also, they have good cashflow as their operating cashflow exceeds earnings.

Disclosure: I've been accumulating this stock since August of last year and have a very large position.

Biosyent Inc (BIOYF) Stock Research Links

BIOYF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 6

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 5

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading

Top 5 Most Recently Viewed Articles

Sisecam Revolutionizes Whisky Packaging with Lightweight Design

Updated Category News Views 98

Sisecam pulled a rabbit out of the hat with its new glass whisky bottle, specifically for Johnnie Walker Blue Label Ultra. This wasn’t just any bottle; it weighed in at a feather-light 180 grams—an astonishing 80% reduction from traditional models. Traders were buzzing when they heard about this during the London Design Festival unveiling, eyeing how such innovation...

Continue Reading
Kelun-Biotech Expands Sacituzumab Tirumotecan Use in Lung Cancer

Updated Category News Views 263

Kelun-Biotech’s Innovative Therapy Gains Approval CHENGDU, China – Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. proudly announces the recent approval of its groundbreaking therapy, sacituzumab tirumotecan (sac-TMT), designed to target specific forms of lung cancer. This approval signifies the third indication for sac-TMT in treating adult patients with epidermal...

Continue Reading
Intel's Smart Moves Propel Stock Recovery: What's Next?

Updated Category News Views 95

Intel's Resurgence in the Tech Landscape Intel Corporation, once thought to be sidelined, entered the year with renewed vigor. Once seen as losing ground in the AI chip domain, the company has managed to reclaim its space through clever partnerships and a decisive reshuffle in leadership. By the start of 2026, the price per share hovered around $41.90, indicating a...

Continue Reading
Five Below Faces Securities Fraud Lawsuit: Know Your Rights

Updated Category News Views 60

Five Below Faces Serious Legal Challenges Five Below, Inc. is currently dealing with significant legal issues following a lawsuit that has been filed against the company and several of its top executives. Investors who put their trust in Five Below are understandably worried about the status of their investments and the company's overall integrity. Details of the Lawsuit...

Continue Reading
Why CrowdStrike's Potential Growth Makes It a Top Buy Right Now

Updated Category News Views 239

Insights into CrowdStrike’s Ongoing Growth Potential CrowdStrike (NASDAQ: CRWD) shows no signs of slowing down, and its growth trajectory in the cybersecurity sector is promising. This year has started with challenges, such as a decline in stock prices driven by lower-than-expected earnings guidance. However, this dip presents a unique opportunity for potential...

Continue Reading